QP releaseQualified Person release

In the European Union (and the UK, post-Brexit), no medicinal product for human or veterinary use is placed on the market without the personal certification of a Qualified Person (QP). The QP is a named, legally identified individual whose signature on the batch release attests that each batch has been manufactured and controlled in accordance with the requirements of the Marketing Authorisation and Good Manufacturing Practice. The QP carries personal legal liability for the certification — if the batch is later found to have been improperly released, the QP can be held personally accountable, up to and including criminal sanctions in some Member States.

The QP concept has no direct US equivalent. In the US, batch release happens under 21 CFR 211.165 by the Quality Unit (a function, not a named individual), with the responsible individual identified internally but not registered with FDA. The EU model is more personal and more demanding: the QP must be on the manufacturing authorisation, must be reachable by the regulator, must be substituted only through a formal change to the authorisation, and signs every release personally.

The QP role is defined in EU primary legislation:

• Directive 2001/83/EC — Article 48 (the QP must be at the disposal of the manufacturing authorisation holder), Article 49 (qualifications: pharmacy, medicine, veterinary, chemistry, pharmaceutical chemistry, biology — plus two years of post-graduate batch certification experience), Article 51 (the QP's obligations — certify each batch, including imports from third countries).
• Directive 2003/94/EC — GMP principles for medicinal products for human use.
• Directive 91/412/EEC — Veterinary equivalent.
• Regulation 726/2004 — Centrally authorised products.
• EU GMP Annex 16 — Detailed expectations for QP certification, the QP's responsibilities for outsourced activities, batch testing in third countries, and certification under the Mutual Recognition Agreements (MRAs).

Annex 16 (2016 revision) is the most operational of these. It defines exactly what the QP must satisfy themselves of before certifying a batch — and gives the regulator a clean reference point during inspection.

Annex 16 §1.6 lists the explicit checks the QP must perform before certifying a batch. The QP signs that they have satisfied themselves of each of these:

1. The batch and its manufacturing comply with the provisions of the Marketing Authorisation.
2. Manufacturing has been carried out in accordance with EU GMP or, in the case of import from a third country, with GMP standards equivalent to those of the EU.
3. The principal manufacturing and testing processes have been validated.
4. All necessary checks and tests have been performed, including any additional sampling, inspection, tests or checks initiated because of deviations or planned changes.
5. All necessary production and quality control documentation has been completed and signed by the staff authorised to do so.
6. All audits have been carried out as required by the QMS.
7. All deviations and OOS results have been investigated and closed, or are formally evaluated and disposition decided.
8. Planned changes and unplanned events affecting the batch have been recorded and approved.
9. Where applicable, the supply-chain traceability for active substances and excipients is documented.
10. Where outsourced, the contract giver has confirmed the contract acceptor's GMP status.
11. The QP is satisfied that the batch is suitable for release.

The QP does not personally re-do the work. The QP confirms — based on the QMS, the batch record, the analytical results, the deviation log, the change-control log, the supplier-audit status and the contract-acceptor confirmation — that the system worked and the batch is fit. The signature is the QP's personal attestation that they have satisfied themselves of each item on the list above.

Directive 2001/83/EC Article 49 lays out the QP's education and experience requirements. The candidate must hold a university degree (or equivalent course of at least four years) in pharmacy, medicine, veterinary medicine, chemistry, pharmaceutical chemistry and technology, or biology. The course must have included specific subjects (experimental physics, general and inorganic chemistry, organic chemistry, analytical chemistry, pharmaceutical chemistry including drug analysis, general and applied biochemistry, physiology, microbiology, pharmacology, pharmaceutical technology, toxicology, pharmacognosy).

After the qualifying degree, the candidate must have at least two years of practical experience in qualitative analysis of medicinal products, quantitative analysis of active substances, and the tests and checks necessary to ensure the quality of medicinal products, in an undertaking authorised to manufacture medicinal products. Some Member States (UK, Ireland, Italy) operate their own assessor schemes — the European QP Association's Joint Code of Practice is the most widely accepted reference.

QPs are personally registered with the national competent authority (MHRA in the UK, BfArM in Germany, ANSM in France, AIFA in Italy). The manufacturing authorisation explicitly names the QPs. A change of QP is a variation to the authorisation; the company cannot simply rotate the role.

For US-EU dual-marketed products, the same physical batch is often released twice: once by the US Quality Unit per 21 CFR 211.165, once by the EU QP per Annex 16. The EU certification may add additional checks the US does not require, but the underlying GMP work is the same.

Annex 16 §3 is the most quoted section in QP practice. It deals with the situation where a deviation, OOS, or other unexpected event affects a batch the QP is being asked to certify.

The default rule: the QP shall not certify the batch unless the deviation has been fully investigated, the root cause identified, the impact on quality / safety / efficacy assessed, and the disposition approved by quality. Where the deviation cannot be fully closed before certification, the QP may certify only if (i) the deviation is fully documented, (ii) the impact is unambiguous and acceptable, and (iii) the QP personally documents the reasoning.

This is where QP discretion is most exposed. A QP who certifies a batch with an open critical deviation is taking personal liability for that decision. A QP who refuses to certify a batch holds the supply chain up — sometimes at significant commercial cost. The QP's independence from commercial pressure is structurally important to the role.

Annex 16 §1.5 explicitly addresses outsourced manufacture: the QP certifying a batch is responsible for the GMP compliance of every step in the supply chain, regardless of whether the step was performed in-house or by a contract acceptor. The QP must satisfy themselves that the contract giver / acceptor relationship is documented, the contract acceptor's GMP status is confirmed, and the work performed is consistent with the Marketing Authorisation.

For products imported from third countries (non-EU), the QP must ensure each batch has been manufactured and controlled in accordance with GMP standards at least equivalent to those of the EU. Where the third country is covered by a Mutual Recognition Agreement (MRA), the QP may rely on the third country's batch certification. Where it is not, the QP must satisfy themselves through audit, testing, and documentation review.

The 2016 Annex 16 revision tightened expectations around the QP's responsibility for the full supply chain, including the active substance manufacturer. The QP can rely on supplier audit, on the company's API supplier qualification programme — but the QP signs as if they did the audit personally.

Historically QP certification was a wet-ink signature on a paper certificate. Modern practice is electronic — QP signs via a controlled e-signature inside the eBMR / MES / QMS platform. EU GMP Annex 11 (computerised systems) and Annex 16 §1.7 together set the expectations: the electronic signature must be unique to the QP, secure, traceable, and bound to the certified record permanently.

The QP must not sign a certification they have not personally reviewed. This sounds obvious but is the most common failure mode in poorly designed e-release systems: the QP is given a single "approve" button without the underlying record being visible in the same workflow. A defensible e-release UI presents the full Annex 16 §1.6 checklist with the supporting evidence linked, requires the QP to advance through each item, and signs against the complete dossier.

The audit trail (Part 11.10(e), Annex 11 §9) must capture: who signed, when, against which exact version of the BMR / MMR / deviation log / analytical certificate; what the QP's signature manifest was (signature meaning per Part 11.50); and any subsequent changes. The certified record is immutable — any subsequent change creates a new version, not an overwrite.

V5 Ultimate ships QP release as a structured workflow against the same record as the eBMR / eDHR / LIMS / QMS. The QP dossier is assembled from execution data — the MMR snapshot the batch ran on, every captured weight / temperature / in-process check, every deviation with disposition, every OOS with investigation, every change-control linked to the batch, every analytical result with the analyst's e-signature and the instrument calibration status, every supplier audit and contract-acceptor confirmation. Annex 16 §1.6 is rendered as a checklist with each item linked to the supporting evidence.

The QP advances through the checklist, drilling into anything that needs personal scrutiny, and signs with a controlled e-signature that binds the certification permanently to the exact version of the batch record. The audit trail captures who, when, against what, with what signature meaning, under Part 11 / Annex 11. The same workflow handles standard releases, deferred releases pending deviation closure, and rejections. Time from "batch complete" to "QP certified" drops from days to hours because the dossier is already assembled — the QP is reviewing, not collating.